药石科技(300725) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥377,460,431.51, a decrease of 1.56% compared to ¥383,440,937.44 in the same period last year[6] - Net profit attributable to shareholders was ¥49,485,359.20, down 14.32% from ¥57,755,969.84 year-on-year[6] - Basic earnings per share decreased to ¥0.25, a decline of 13.79% from ¥0.29 in the previous year[6] - Total operating revenue for Q1 2024 was CNY 377,460,431.51, a decrease of 1.5% compared to CNY 383,440,937.44 in Q1 2023[22] - Net profit for Q1 2024 was CNY 49,485,359.20, down 14.3% from CNY 57,755,961.44 in the same period last year[23] - The total comprehensive income for the first quarter of 2024 was CNY 49,626,884.56, a decrease from CNY 56,505,995.48 in the same period last year, representing a decline of approximately 12.5%[24] Cash Flow - The net cash flow from operating activities was ¥55,330,257.73, down 26.24% from ¥75,015,353.97 in the same period last year[6] - The company's cash and cash equivalents were CNY 792,815,660.74, down from CNY 988,200,226.50, a decrease of approximately 19.7%[20] - Cash inflow from investment activities totaled CNY 478,661,207.44, significantly higher than CNY 119,249,255.06 in the previous year, marking an increase of about 301.5%[27] - The net cash flow from investment activities was CNY 68,930,043.73, a substantial improvement from a negative CNY 539,946,998.48 in the same period last year[27] - Cash and cash equivalents at the end of the period were CNY 440,098,278.17, down from CNY 820,190,549.66 at the end of the previous year, representing a decrease of approximately 46.4%[27] - Total cash outflow from operating activities was CNY 409,432,971.35, compared to CNY 352,108,930.74 in the previous year, indicating an increase of approximately 16.3%[27] - The company incurred a cash outflow of CNY 196,106,641.68 from financing activities, a significant increase from CNY 62,089,206.73 in the previous year, representing an increase of about 215.5%[27] Assets and Liabilities - Total assets at the end of the period were ¥4,962,143,722.24, a decrease of 2.78% from ¥5,104,032,178.39 at the end of the previous year[6] - Total liabilities decreased to CNY 2,086,964,595.18 from CNY 2,271,754,945.18, a reduction of about 8.1%[20] - The company’s long-term borrowings were CNY 47,740,277.77, a slight decrease from CNY 50,034,657.53[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 36,447, with no preferred shareholders[11] - The largest shareholder, Yang Minmin, holds 20.69% of shares, amounting to 41,307,019 shares, with 8,300,000 shares pledged[11] - The top 10 shareholders collectively hold a significant portion of the company's shares, with the largest holding being 20.69%[11] - The company reported a total of 5,756,792 shares held by Henan Hengtong Boyuan Venture Capital Partnership, accounting for 2.88% of total shares[12] Revenue Breakdown - Revenue from drug research stage products and services was CNY 85,365,502.77, accounting for 22.62% of total revenue, up 5.45% year-over-year[16] - Revenue from drug development and commercialization stage products and services was CNY 291,938,068.80, down 3.45% from the previous year[16] Operating Costs and Expenses - Total operating costs decreased to CNY 325,204,409.51 from CNY 344,985,836.29, reflecting a reduction of approximately 5.8%[22] - Research and development expenses were CNY 34,513,051.40, a decrease of 28.6% compared to CNY 48,393,224.73 in Q1 2023[23] - The company reported a gross profit margin of 13.8% for Q1 2024, compared to 10.0% in Q1 2023[22] Taxation - The company recorded a 54.13% increase in taxes and surcharges, amounting to ¥5,103,201.63, in line with the company's expanded scale[9] - The company experienced a 68.07% decrease in tax refunds received, totaling ¥9,329,340.32, due to reduced export tax rebates[10]